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Abstract
Background: Bone resorption is initiated by osteoclastic acidification of the resorption lacunae. This process is
mediated by secretion of protons through the V-ATPase and chloride through the chloride antiporter ClC-7. To
shed light on the intracellular signalling controlling extracellular acidification, we screened a protein kinase inhibitor
library in human osteoclasts.
Methods: Human osteoclasts were generated from CD14+ monocytes. The effect of different kinase inhibitors on
lysosomal acidification in human osteoclasts was investigated using acridine orange for different incubation times
(45 minutes, 4 and 24 hours). The inhibitors were tested in an acid influx assay using microsomes isolated from
human osteoclasts. Bone resorption by human osteoclasts on bone slices was measured by calcium release. Cell
viability was measured using AlamarBlue.
Results: Of the 51 compounds investigated only few inhibitors were positive in both acidification and resorption
assays. Rottlerin, GF109203X, Hypericin and Ro31-8220 inhibited acid influx in microsomes and bone resorption,
while Sphingosine and Palmitoyl-DL-carnitine-Cl showed low levels of inhibition. Rottlerin inhibited lysosomal
acidification in human osteoclasts potently.
Conclusions: In conclusion, a group of inhibitors all indicated to inhibit PKC reduced acidification in human
osteoclasts, and thereby bone resorption, indicating that acid secretion by osteoclasts may be specifically regulated
by PKC in osteoclasts.
Background
Bone is continuously remodeled throughout life to react
to stress on the skeleton and to repair microfractures
[1-3]. Bone is resorbed by the osteoclasts and new bone
is formed by the osteoblasts [4]. Bone resorption is
mediated through acidification of the resorption lacunae
by the osteoclasts. The mineralized bone matrix is dis-
solved by secretion of protons through a V-ATPase
[5-8], which is followed by chloride transport through
ClC-7 to maintain electroneutrality [9-13]. At the low
pH in the resorption lacuna cathepsin K degrades the
organic phase of the bone [14,15]. The importance of
the acidification process in osteoclasts is illustrated by
mutations in the a3 subunit of the V-ATPase and in
ClC-7, which lead to osteopetrosis [12,13,16-18].
Furthermore, inhibitors of acid secretion by the osteo-
clasts have been shown to have promising effects, and
are being investigated as potential drug candidates for
osteoporosis at the moment [19,20].
The intracellular mechanism underlying acid secretion
appears to involve Protein Kinase A (PKA) and Protein
Kinase C (PKC) [21,22], as a study implicated PKA as a
negative regulator of acid secretion in rat osteoclasts
[23], and another study showed effects with different
tyrosine kinase inhibitors in avian osteoclasts [24]. PKC
has also been implicated in the acid secretion process in
avian osteoclasts, an effect related to reduction of V-
ATPase activity [25]. In avian osteoclasts the tyrosine
kinase c-src regulates osteoclastic acid secretion through
the chloride channel CLIC5b [26], however, these find-
ings appear to be specific for the avian osteoclasts as
they were not reproduced in a human osteoclast based
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system [27], where ClC-7 appears to be the chloride
channel of importance [10,28]. In summary there is no
consensus on the intracellular control of acid secretion
in human osteoclasts.
We investigated whether protein kinases play roles in
mature human osteoclasts, and whether the roles are
related to acid secretion using inhibitors of these kinases
and their specific isoform. We used a panel of protein
kinase inhibitors in acridine orange based acid secretion
assays in whole cells and membrane fractions, as well as
human osteoclasts seeded on cortical bone slices to eval-
uate the effect of the inhibitors on bone resorption.
Methods
Chemicals
Chemicals were obtained from SIGMA-ALDRICH A/S
and culture media from LIFE TECHNOLOGIES A/S
unless specified. Bafilomycin was obtained from Tocris,
while the different kinase inhibitors were obtained from
BIOMOL International LP.
Cell culture
The CD14+ isolation was performed as previously
described [29]. Briefly, the monocytes were isolated
from peripheral blood by centrifugation on a Ficoll-
Paque gradient (Amersham Pharmacia), and magneti-
cally sorted using a CD14+ magnetic bead isolation kit
(Dynal Biotech). The cells were then seeded in 75 cm2
flasks, and cultured in aMEM containing 10% fetal calf
serum, 100 units/mL penicillin, 100 μg/mL streptomycin
and 25 ng/ml of M-CSF for three days, then they were
lifted using trypsin and a cell scraper, and cultured until
day 10 in the presence of 25 ng/ml M-CSF and 25 ng/
ml RANKL (R&D Systems) unless otherwise stated.
The blood was received from the blood bank at the
University Hospital of Copenhagen from volunteer
donors, which all sign informed consent that the blood
can be used for research purposes. The approval is held
by the University Hospital of Copenhagen.
Osteoclast resorption
Mature human osteoclasts were lifted from culture
flasks and subsequently seeded on cortical bovine bone
slices at a density of 20,000 cells/cm2 and then culture
for 5 days, with refreshment of medium once. The
supernatant was collected and the release of calcium
was measured. Inhibitors of resorption were added in
the medium at different concentrations and compared
to vehicle treated osteoclasts (DMSO).
Cortical bovine bone slices
The bone slices were cut from sticks (Nordic Bioscience
A/S), which were made of the cortical bone from cows.
The sticks were cut into small slices with a thickness of
0.2 mm with a diameter that fits into 96 well plates.
Measurement of calcium
The concentration of total calcium was measured in the
culture supernatants after resorption using a colori-
metric assay and a Hitachi 912 Automatic Analyzer
(Roche Diagnostics).
Osteoclast acidification assay
Acridine orange (3,6-bis[Dimethylamine]acridine) at 10
μg/ml was loaded for 45 min in the culture medium in
the presence or absence of various inhibitors as
described previously [27]. The dye was washed away and
pictures were taken using an Olympus IX-70 micro-
scope and an Olympus U-MWB filter (x20 objective), or
fluorescence was measured using the SpectraMax M5
(Molecular Devices) at excitation 492 nm and emission
535 nm. The results are presented as percentage of the
signal obtained with the positive control Bafilomycin
treated condition.
AlamarBlue assay
To assess cell viability AlamarBlue measurements were
performed according to the manufacturer’s protocol
(Trek Diagnostics Systems Inc.). Briefly, AlamarBlue was
diluted 1 to 10 in the cell culture medium, and the
color change was monitored carefully. When a switch
from blue to purple was observed, the color changes
were measured using a plate reader (excitation wave-
length 540 nm, emission 590 nm). Medium without
cells was used as background. The cell viability was
measured in mature human osteoclasts seeded on bone
slices after the 5-day culture period at termination.
Osteoclast microsomes
The osteoclast-derived membrane vesicles were isolated
using a modification of a protocol published by [28].
Briefly, the mature cells were washed two times in PBS,
and the cells were lifted by scraping in 10 mM Tris-
HCl, 4 mM EDTA pH7.4 containing Complete Mini
EDTA-free protease inhibitor tablet. The collected cells
were then homogenized using an Ultraturrax blender
and a Teflon homogenizer, and then the homogenized
cells were centrifuged at 700 g to eliminate iron beads
and cell remnants. The homogenates were then ultra-
centrifuged at 40,000 g for 30 minutes, and finally the
pellet was resuspended and stored at -80°C until further
use.
Influx assay
The influx assay was performed as previously described
[27,28]. Briefly, osteoclast membranes were incubated in
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reaction buffer [27]. The reaction was incubated at room
temperature for 30 minutes to obtain a steady state.
Then the reaction was initiated by addition of ATP at a
concentration of 5 mM, and immediately after the plate
was read in a plate reader using excitation 492 nm and
emission 535 nm. The fluorescence was read every 15
seconds for three minutes. The results are presented as
the slope of the influx curves in percent of the vehicle,
which represents the rate of the acidification (ΔF/Δt).
Immunoblotting
Total cell lysates were prepared by lysing the osteoclasts
in RIPA+++ buffer for 5 min [12]. The lysates were cen-
trifuged at 15,000 g for 30 min to remove any cell debris
left. Osteoclast membranes were prepared as described
in the paragraph “osteoclast microsomes”. Protein con-
centrations were measured using the Bio-Rad DC pro-
tein measurement assay. Ten micrograms of total
protein for either the lysate or the membranes were
loaded onto a SDS-PAGE gel in sample buffer contain-
ing 10 mM dithiotreitol, and electroblotted onto nitro-
cellulose membranes. The quality of the protein loading
was checked by Ponceau Red staining. The membranes
were then blocked in TBS-T (50 mM Tris-base pH 7.5,
100 mM NaCl, 0.1% Tween-20) containing 5% skim
milk powder for 1 h at ambient temperature. This was
followed by overnight incubation at 4°C with the correct
dilution of the primary antibodies against PKC (A-3)
(Santa Cruz) and V-ATPase B2 (Santa Cruz). This was
followed by incubation with the corresponding horse-
radish peroxidase-conjugated secondary antibody for 1 h
at ambient temperature. Finally, the results were visua-
lized using the ECLTM kit (Amersham Pharmacia
Biotech).
Statistical analysis
Statistical analyses were performed using one-way analy-
sis of variance followed by Dunnett’s multiple compari-
son tests. Bartlett’s test was used to assess variance
homogeneity. Statistical significance is indicated by the
number of asterisks, p < 0.05*, P < 0.01** and p <
0.001***.
Results
Protein kinase inhibitors in osteoclasts
51 protein kinase inhibitors were tested at 10 μM and at
50 μM (data not shown, since 50 μM led to more toxi-
city, without any more specific effects) in a panel of
osteoclastic acidification and resorption assays revealing
that several inhibitors were positive in bone resorption,
i.e. the c-src tyrosine kinase inhibitors PP1 and PP2 as
expected (Table 1 &[30]). In addition, we found that the
tyrosine kinase inhibitor Tyrphostin 47 inhibited acid
influx, as previously published, on the other hand
Genistein, another tyrosine kinase inhibitor, did not
show any inhibitory effects in the tested assays [24]. The
mTOR inhibitor Rapamycin showed a minor inhibition
of acid influx and bone resorption, without affecting
survival, although this was expected from earlier studies
[31,32]. All in all few compounds were positive in all
assays, and in these cases other inhibitors of the same
target failed to reproduce the data indicating that the
effects were due to non-specific effects (data not
shown). However, inhibitors, which are speculated to
inhibit PKC showed consistent inhibition of both acid
secretion and bone resorption, and thus were analysed
in detail. All the results are summarised in Table 1.
The effect of potential PKC inhibitors on lysosomal
acidification in mature human osteoclasts
The acridine orange assay is based on a dye that fluor-
esces bright orange at lysosomal pH, and becomes green
at neutral pH. It has previously been shown to be useful
in relation to quantification of lysosomal pH changes in
whole cells, as well as microsomal membranes [27,33],
and therefore we used it to assess the effects of various
potential PKC inhibitors in detail. GF109203X, Hyperi-
cin, Ro31-8220, Sphingosine, HBDDE and Palmitoyl-
DL-carnitine-Cl were analyzed, and of these inhibitors,
only GF109203X showed inhibition of lysosomal acidifi-
cation and only at the 45 minute time point (Figure
1A), whereas the others were ineffective. These data
were confirmed using quantitative analysis (Figure 1B).
All inhibitors were tested after 45 minutes, 4 and 24
hours. However, only the 45 minutes results are shown
in figure 1. In addition, Rottlerin was characterized in
detail. Rottlerin inhibited lysosomal acidification already
after 45 minutes incubation both in the qualitative and
the quantitative assay. Due to the potent inhibition
observed using Rottlerin further concentrations were
tested, and as seen in figure 2, these data clearly show
that Rottlerin dose-dependently inhibits lysosomal acidi-
fication at 45 minutes (Figure 2), 4 and 24 hours (data
not shown). In the acidification experiments Bafilomycin
A1 was used as a positive control in accordance to pre-
viously published studies [27,33].
The effect of potential PKC inhibitors on acid influx in
human osteoclast microsomes
To further characterize the effects of the inhibitors, we
used a membrane-based acid influx assay based on
microsomes previously shown to be enriched in ClC-7
indicating a high content of lysosomes, which are the
desired sub-cellular fraction [27,28]. This assay is based
on microsomes from human osteoclasts and it is highly
sensitive to the V-ATPase inhibitor Bafilomycin A1,
which was used as a positive control (Figure 3H)
[27,28].
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Inh at 10 μM
Alamar - %
Inh. at 10 μM
PDGFRK AG-370 20 No No 20 Yes 0 0
AG-1296 1 No No 15 Yes 0 0
EGFRK/PDGFRK AG-494 1.2 No No 55 No 0 0
Tyrphostin 46 9.2 No No 0 No 0 0
EGFRK Lavendustin A 0.011 No No 0 No 0 0
RG-14620 3 No No 0 No 0 0
Tyrphostin 23 35 No No 45 Yes 0 0
Tyrphostin 25 3 No No 34 Yes 0 0
Tyrphostin 47 2.4 No No 85 No 0 0
Tyrphostin 51 0.8 No No 0 No 0 0
Tyrphostin
AG1478
0.003 No No 0 No 43 0
Erbstatin (a) 0.77 No No 0 No 0 0
Erlotinib 1 No No 0 No 100 100
NGFRK AG-879 10 No No 100 No 22 0
EGFRK/CaMKII Lavendustin C 2 No No 0 No 0 0
CaMKII KN-62 0.9 No No 0 No 63 0
KN-93 0.37 No No 40 No 0
MEK1/2 PD-98059 2 No No 0 No 0 0
U-0126 0.072 No No 0 No 0 0
p38MAPK SB203580 0.07 No No 0 No 0 0
PKA, PKG, MLCK,
PKC
H-7 3.0 No No 0 No 0 0
H-9 1.9 No No 0 No 0 0
PKC GF-109203X 0.02 Yes No 100 No 100 0
Hypericin 3.4 No No 82 Yes 100 95
Ro 31-8220 0.01 No No 79 Yes 100 100
Sphingosine 1-3 No No 15* No 0 0
Palmitoyl-DL- 25 No No 17* No 0 0
Carnitine-Cl
PKCδ Rottlerin 3-6 Yes No 100 No 100 90
PKCa/g HBDDE 43 No No 58 Yes 0 0
PKA H-89 0.048 No No 0 No 0 0
PKA/PKG H-8 0.48 No No 0 No 0 0
HA-1004 30 No No 0 No 0 0
HA-1077 1.6 No No 0 No 0 0
HER1-2 AG-825 0.35 No No 43 Yes 0 0
Tyrosine Tyrphostin
AG1288
21 No No 88 No 0 0
Kinases Tyrphostin
AG1295
25 No No 0 No 0 0
Genistein 0.002 No No 0 No 0 0
IRK HNMPA 10 No No 0 No 0 0
JNK SP 600125 0.04 No No 0 No 0 0
p56 lck Damnacanthal 0.017 No No 0 No 47 0
Syk Piceatannol 10 No No 0 No 0 0
Src family PP1 0.005 No No 0 No 78 0
PP2 0.004 No No 0 No 100 45
JAK-2 AG-490 ~5 No No 0 No 0 0
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GF109203X (Figure 3A), Hypericin (Figure 3B), and
Ro31-8220 (Figure 3C) inhibited acid influx albeit with
different potencies, whereas the compounds Sphingosine
(Figure 3D) and Palmitoyl-DL-carnitine Cl (Figure 3E)
showed only low levels of inhibition, likely due to low
potency, or alternatively due to phase partitioning into
the lipid bilayer since these molecules are lipid-like. Of
these general PKC inhibitors, GF109203X inhibited acid
influx potently. In addition, Rottlerin inhibited the acid
influx potently and to the same level as GF109203X
(Figure 3G), while HBDDE showed some inhibition of
acid influx (Figure 3F).
The effect of potential PKC inhibitors on bone resorption
by human osteoclasts
To investigate whether the effects of the inhibitors in
the acidification assays were paralleled by inhibition of
bone resorption by human osteoclasts, the different
compounds were tested in a dose-response, again using
Bafilomycin A1 as a positive control (figure 4H) [27,28].
All the inhibitors, except HBDDE, reduced bone
resorption (Figure 4 and table 1), and their potencies in
the resorption assay correlated well with the potencies
observed in the acidification-based assays, with
GF109203X being the most potent and Palmitoyl-DL-
Table 1 Summary of data for all inhibitors (Continued)
ERK2, CK1, CK2 5-
Iodotubercidin
0.4 No No 0 No 100 100
cRAF GW 5074 0.009 No No 80 Yes 58 0
IKK pathway BAY 11-7082 5 No No 100 No 0 0
GSK-3b/CDK5 Indirubin-3’-
monoxime
0.022 No No 0 No 72 0
mTOR Rapamycin 0.010 No No 46 No 40 0
Neg. Cont. Tyr
Kinase Inhibitor
Tyrphostin 1 NA No No 0 No 0 0
Neg. Cont.
Genistein
Diadzein NA No No 0 No 0 0
The table summarizes data for the acidification assay using acridine orange (45 minute incubation) and the %-inhibition in the acid influx assay at 10 μM. It is
stated whether the compounds quench the acridine orange signal. The %-inhibition in the bone resorption and AlamarBlue assay are also provided for each
inhibitor tested. *Indicates auto fluorescence of the compound. Text in italics shows the compounds shown in the figures. # indicates lowest IC50 values
obtained in relevant assays http://www.enzolifesciences.com. NA indicates not applicable (for negative controls).
Figure 1 The effect of potential PKC inhibitors on acid secretion. Human CD14+ monocytes were isolated from blood and seeded in 96
well plates and cultured in the presence of 25 ng/ml M-CSF and RANKL for 12 days. The mature human osteoclasts were incubated for 45
minutes with acridine orange alone or in combination with the following compounds: GF109203X, Hypericin, Ro31-8220, Sphingosine, Palmitoyl-
DL-carnitine-Cl, HBDDE or Bafilomycin A1 (200 nM) as a positive control. All the results are presented as % of Bafilomycin. A) Acridine Orange
pictures showing the effect of the inhibitors. B) Acridine Orange readings of the green wavelength (Excitation 492 nm - emission 535 nm) was
measured using a SpectraMax M5 showing the effect of the inhibitors. The results are representative of three individual experiments performed
in quadruplicates. The asterisks indicate significant differences between vehicle and inhibitor treated conditions.
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Carnitine Cl the least potent. Some toxicity of the com-
pounds was observed. Only GF109203X was not toxic at
the tested concentrations up to 10 μM (figure 4A),
while Hypericin (figure 4B) showed toxicity at 10 μM
but not at 1 μM and therefore a separation between
inhibition of resorption and reduction of cell viability
was seen. Palmitoyl-DL-Carnitine D1 (figure 4E) inhib-
ited bone resorption at a high concentration, and at 90
μM the compound showed toxicity, thus making it diffi-
cult to distinguish real anti-resorptive effects from toxi-
city. In addition, Ro31-8220 and Sphingosine exhibited
toxic effects (Figure 4C and 4D).
Rottlerin potently inhibited bone resorption (Figure 4G),
whereas HBDDE had no effect (Figure 4F). Furthermore,
Rottlerin reduced cell viability; however, as seen for the
other inhibitors there was a clear distinction between the
effect on bone resorption and the effect on cell viability.
Detection of PKC by Western blotting
To ensure that PKC was present in the microsomes, iso-
lated from the human osteoclasts, used to analyze acid
influx, Western blotting was performed. As a reference
a whole cell lysate from human osteoclasts was also ana-
lyzed. PKC (80 kDa) was found in both the osteoclast
membranes and in the osteoclast lysate (Figure 5). In
addition, V-ATPase B2 was used as a positive control
and was shown to be expressed in both osteoclast lysate
and osteoclast membranes as expected [28,34].
Discussion
Previous studies have indicated that various types of
protein kinases are involved in acid production by
osteoclasts from various species; however, whether this
is true for pure human osteoclasts was not clear. We
have used a panel of inhibitors targeting a broad range
of protein kinases in a recently published series of assays
[27] to investigate how acid secretion and bone resorp-
tion by mature human osteoclasts are controlled.
We found that very few of the inhibitors inhibited
more than one process, if any at all, in the osteoclasts
(see table 1), although the inhibitors were used at con-
centrations, which often far exceeded their reported
IC50 values. Surprisingly our data showed that the c-src
kinase inhibitors PP1 and PP2 had no effect on acidifi-
cation, although this has previously been published
using avian osteoclasts [26]. As expected both c-src inhi-
bitors reduced bone resorption [30]. One possible expla-
nation for this discrepancy is the species difference, as
previous studies have indicated that the regulation of
acid secretion between human and avian osteoclasts is
different also with respect to the chloride channels
involved [11,26-28]. Further supporting the difference
between human and avian osteoclasts, we did not find
any inhibitory effects of Genistein, neither on resorption
nor acid secretion, which is in contrast to the findings
of Williams et al. [24]. Furthermore, other studies have
highlighted that Genistein reduces bone resorption
Figure 2 Effect of Rottlerin on acid secretion. Human CD14+ monocytes were isolated from blood and seeded in 96 well plates and cultured
in the presence of 25 ng/ml M-CSF and RANKL for 12 days. The mature human osteoclasts were incubated for 45 minutes with acridine orange
alone or in combination with different concentrations of Rottlerin or Bafilomycin A1 (200 nM) as a positive control. All the results are presented
as % of Bafilomycin. A) Acridine Orange pictures showing the effect of Rottlerin. B) Acridine Orange readings of the green wavelength (Excitation
492 nm - emission 535 nm) was measured using a SpectraMax M5 showing the effect of Rottlerin. The results are representative of three
individual experiments performed in quadruplicates. The asterisks indicate significant differences between vehicle and inhibitor treated
conditions.
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[35-37], but these results were found in differentiating
osteoclasts. In addition, Genistein has been indicated to
activate PPARg [38], a receptor involved in osteoclasto-
genesis, again showing that it attenuates osteoclastogen-
esis [39]. With respect to effects of Genistein, and the
other general tyrosine kinase inhibitors (Tyrphostin
AG1288 and Tyrphostin AG1295) on mature osteo-
clasts, we were surprised that they did not have any
effects on bone resorption or osteoclast viability, since
these effects were expected due to inhibition of c-src
and c-fms [24,40-43]. We speculate that the combina-
tion of short time span, the low potency and selectivity
of these compounds combined with the high doses of
RANKL and M-CSF used in the culture system are the
causes for the lack of effect of these compounds.
In osteoclasts of various origin both PKA and PKC
have been associated with acid secretion under different
circumstances [23,25], and thus their roles in the regula-
tion of acid secretion were of high interest; however, no
effects of the PKA inhibitors were detected. This corre-
lates with the findings of Kajiya et al. [23], who found
that PKA activators inhibited acid secretion in rat osteo-
clasts, and that PKA inhibitors protected against calcito-
nin mediated inhibition of acid secretion. In contrast, it
Figure 3 The effect of potential PKC inhibitors on acid influx. Acid influx in microsomes isolated from human mature osteoclasts was
investigated using the dye acridine orange as described in the materials and methods section. All compounds were tested in a dose-response.
A) GF109203X, B) Hypericin, C) Ro31-8220, D) Sphingosine, E) Palmitoyl-DL-carnitine-Cl, F) HBDDE, G) Rottlerin or H) Bafilomycin A1. The results
are representative of three individual experiments performed in quadruplicates. The asterisks indicate significant differences between vehicle and
inhibitor treated conditions.
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was shown that inhibition of PKA-cAMP signaling
reduced bone resorption by mouse osteoclasts [44],
however, we could not reproduce these findings using
PKA inhibitors in the human system, indicating that dif-
ferent species of osteoclasts utilize different signaling
cascades to control bone resorption.
The most potent inhibitors of acid influx and bone
resorption were all compounds indicated to inhibit PKC.
The most potent inhibitor of acid influx and bone
resorption was GF109203X, which is known to be some-
what selective for PKC [45]. In the cell-based acidifica-
tion assay GF109203X inhibited only at 45 minutes, but
not at the other time points, due to a yet unidentified
reason. Interestingly Rottlerin, a molecule indicated to
inhibit the PKCδ isoform was equally potent as
GF109203X but in addition it also inhibits the acidifica-
tion in intact human osteoclasts. These data indicate
that PKC and maybe more specific PKCδ plays a role in
controlling acid secretion, and thus bone resorption by
human osteoclasts. These data correlate well with a
study implicating PKC as involved in the acid secretion
in avian osteoclasts [25]. Furthermore, studies have indi-
cated that PKC is involved in transient shape changes in
osteoclasts [46,47]; however, whether these changes
Figure 4 The effect of potential PKC inhibitors on osteoclastic bone resorption. Mature human osteoclasts were seeded on cortical bovine
bone slices, and allowed to attach for 3 hours. Hereafter, dose-responses of the following compounds: A) GF109203X, B) Hypericin, C) Ro31-
8220, D) Sphingosine, E) Palmitoyl-DL-carnitine-Cl, F) HBDDE, or G) Rottlerin was added to the cells. H) Bafilomycin A1 was used as a positive
control. After five days of culture calcium release was measured in the culture supernatants. AlamarBlue was used to measure the cell viability
after five days of culture. The results are presented as relative inhibition compared to vehicle treated osteoclasts. The results are representative of
three individual experiments performed in quadruplicates. The asterisks indicate significant differences between vehicle and inhibitor treated
conditions.
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have anything to do with lowered acidification remains
to be clarified.
Toxicity was observed for Rottlerin in the bone
resorption assay, but only at the 10 μM concentration.
However, the inhibitor effect of Rottlerin on acid influx
and bone resorption was apparent at lower doses, indi-
cating that inhibition of acid influx and bone resorption
is through PKC inhibition at low concentrations, while
the high concentrations non-specific effects lead to toxi-
city, such as those described in the following section.
However, although Rottlerin has been shown to be a
potent inhibitor of PKCδ [48], others have shown that
Rottlerin has several other effects, and for example it
strongly suppresses CHK2, PLK1, PIM3, SRPK1 [49],
p38-MAPK, PKA and GSK-3b [50]. Furthermore, it has
been shown that Rottlerin decreases RANK expression
in macrophages, most likely by a PKC-independent
pathway [51]. However, the cells used by Kang et al.
[51] were U937 cells, which are used to study differen-
tiation of monocytes to macrophages. An osteoclasts
precursor cell cannot be compared to the system with
mature human osteoclasts used in this study. In addi-
tion, the RANK expression does not affect the acidifica-
tion, and Rottlerin seems to inhibit acidification in the
mature human osteoclasts.
Like Rottlerin, GF109203X has also been shown to
have other effects than as a PKC inhibitor. It has for
example been shown to inhibit C1q-induced P-selectin
expression [52], inhibition of activated ERK [53], and
inhibition of NHE1 activity [54].
These findings indicate that both Rottlerin and
GF109203X are too weak and non-specific inhibitors to
be useful in cell-based studies. Furthermore, other off
target effects of Rottlerin on mitochondrial function
[55,56], and as a protonophore [57], question whether
the effect we observed is indeed through inhibition of
PKCδ. A protonophore will collapse all acid transport
[58], however, it appears unlikely that collapsing all pro-
ton gradients will not affect osteoclast survival, and thus
we speculate that the inhibition of resorption is unre-
lated to the protonophore effect. Furthermore, other
inhibitors indicated to inhibit PKC also reduced acid
secretion and bone resorption, potentially indicating a
role of PKC in osteoclast-mediated acidification,
although the specificity of all inhibitors should be inter-
preted with skepticism [50,59].
With respect to the commercially reported in vitro
IC50 values, our data do not always correlate well with
these, as underlined by the fact that both rottlerin and
GF109203X both are very potent in our assays, and yet
their in vitro IC50 values are far apart (see table 1).
Furthermore, as illustrated throughout the manuscript
IC50 values are highly assay dependent, and thus com-
parison of IC50 values between assays is difficult and
should be done considering all the factors in play, such
as membrane-permeability, access to the ruffled border,
and the assay itself.
Furthermore, the discrepancies between acid influx and
acidification in intact osteoclasts are not fully clear yet.
Some of the inhibitors are effective inhibitors of bone
resorption and acid influx, but they do not inhibit the
acidification in whole cells. This can be because of the
concentration and time-line used for the acidification
study in whole cells. The bone resorption assay is a 5-day
assay and could lead to more false positives due to this,
compared to the acidification assay in which up to 24
hours incubation were tested. Henriksen et al. [27] have
previously shown that the high concentrations needed to
observe inhibition in the cell-based acridine orange assay
can lead to unclear results. In addition, the acid influx
data often correlates better with the effects on bone
resorption. These findings are further illustrated by the
discrepancies between the time-line for inhibition of cell-
based acridine orange between GF109203X and Rottlerin.
However, in acid influx assay problems due to quenching
of the acridine orange signal are seen leading to false
positive in the assay. Confirming the relevance of study-
ing PKC in membrane fractions, we found that PKC is
indeed present in the osteoclast microsomes, and since it
is well-known that PKC can be found in two conforma-
tions; an inactive and an active form, of which the active
is membrane-bound [60-62]. Thus, the system used in
the influx assay contains PKC in its active membrane
bound conformation.
For the validation of the results found in this study,
using siRNA would be of interest, and could in the
future provide important data. However, due to
Figure 5 Detection of PKC in both osteoclast membranes and
osteoclast lysate. CD14+ monocytes were cultured in the presence
of M-CSF and RANKL for 12 days to mature osteoclasts were
present. The osteoclasts were either used to make a lysate of
mature human osteoclasts using RIPA+++, or they were used for
microsome isolation. The expression of PKC, together with V-ATPase
B2 as a positive control, was analyzed by loading 10 μg of lysates
and microsomes on SDS-PAGE gels with subsequent
immunoblotting.
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difficulties in getting robust transfection and knock-
down in human osteoclasts, this has not yet been
feasible.
Conclusions
In this study we presented the analysis of a panel of
protein kinase inhibitors in acidification of the resorp-
tion lacunae and bone resorption by human osteoclasts.
However, it should be noted that some of the results are
clouded by the difficulties involved in separating toxic
effects from relevant inhibitory effects, as well as separ-
ating inhibition of fluorescent signals from quenching
related effects, especially at the high concentrations used
for some of the compounds. Furthermore, the specificity
of the inhibitors is often not very high, and this is
clearly illustrated by the fact that one of the most potent
inhibitor of bone resorption and acid secretion, Rottle-
rin, has been indicated to exert a function as a proton-
ionophore [63], which thus would explain its highly
potent effect in all the assays. However, the compound
is not overtly toxic in the long term cultures used for
testing bone resorption, which is surprising for a com-
pound eliminating all proton gradients in a whole cell.
Furthermore, our finding that both GF109203X and
Rottlerin inhibit acid secretion and bone resorption
potently, support a role for PKC in the acidification pro-
cess in human osteoclasts.
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